Virax COO reports stock option holdings

Virax Biolabs Group Ltd director and Chief Operating Officer Nigel William McCracken filed an initial Form 3 disclosing stock option holdings.

Rhea-AI Filing Summary

Virax Biolabs Group Ltd director and Chief Operating Officer Nigel William McCracken filed an initial Form 3 disclosing stock option holdings. He holds options over 20,000 ordinary shares at an exercise price of $3.6000 expiring on September 1, 2033, 50,000 shares at $0.6800 expiring on April 18, 2034, and two grants over 20,584 and 29,416 shares at $0.8800 expiring on April 8, 2035. Footnotes state these options were granted under the company’s 2023 and 2024 Equity Incentive Plans and vest in equal thirds over three years, with vested portions becoming exercisable upon vesting.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider McCracken Nigel William

Role Chief Operating Officer

Type	Security	Shares	Price	Value
holding	Stock Options (right to buy)	--	--	--
holding	Stock Options (right to buy)	--	--	--
holding	Stock Options (right to buy)	--	--	--
holding	Stock Options (right to buy)	--	--	--

Holdings After Transaction: Stock Options (right to buy) — 120,000 contracts (Direct)

Footnotes (4)

1. F1. On September 1, 2023, the Company granted 20,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on September 1 of each of 2024, 2025 and 2026. The vested portions of such options will become exercisable upon vesting.
2. F2. On April 18, 2024, the Company granted 50,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting.
3. F3. On April 8, 2025, the Company granted 20,584 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.
4. F4. On April 8, 2025, the Company granted 29,416 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Virax Biolabs (VRAX) Form 3 filing disclose?

The Form 3 discloses that COO and director Nigel William McCracken holds several stock option awards over Virax ordinary shares. These options were granted under the 2023 and 2024 Equity Incentive Plans and vest in equal thirds over future years before becoming exercisable.

How many Virax Biolabs (VRAX) options does Nigel McCracken hold?

Nigel McCracken holds options over 20,000 shares at $3.6000, 50,000 shares at $0.6800, and additional grants of 20,584 and 29,416 shares at $0.8800. All relate to ordinary shares and are classified as directly owned derivative securities.

What are the exercise prices and expirations of the VRAX options reported?

The filing lists option exercise prices of $3.6000, $0.6800, and $0.8800. Expiration dates are September 1, 2033, April 18, 2034, and April 8, 2035, respectively, reflecting long-dated incentive awards tied to Virax ordinary shares.

How do the Virax Biolabs (VRAX) options for Nigel McCracken vest?

Each option grant vests in equal thirds over three years, according to the footnotes. The September 2023 grant vests annually from 2024 to 2026, the April 2024 grant from 2025 to 2027, and the April 2025 grants from 2026 to 2028, with vested portions then exercisable.

Is the Virax Biolabs (VRAX) Form 3 a buy or sell transaction?

The Form 3 does not report any buy or sell transactions. It is an initial ownership statement that records existing stock option awards held by Nigel McCracken, rather than new market trades or option exercises in Virax ordinary shares.

What equity incentive plans are referenced in the VRAX Form 3 footnotes?

The options were granted under Virax’s 2023 Equity Incentive Plan and 2024 Equity Incentive Plan. Footnotes specify which grant belongs to each plan and describe the three-year, equal-third vesting schedule that determines when each award becomes exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/20/2026 - 10:43 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

McCracken Nigel William

(Last) (First) (Middle)

BIOCITY GLASGOW BO'NESS ROAD

NEWHOUSE LANARKSHIRE

(Street)

MOTHERWELL LANARKSHIRE UNITED KINGDOM ML1 5UH

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Virax Biolabs Group Ltd [ VRAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	(1)	09/01/2033	Ordinary Shares	20,000	$3.6	D
Stock Options (right to buy)	(2)	04/18/2034	Ordinary Shares	50,000	$0.68	D
Stock Options (right to buy)	(3)	04/08/2035	Ordinary Shares	20,584	$0.88	D
Stock Options (right to buy)	(4)	04/08/2035	Ordinary Shares	29,416	$0.88	D

Explanation of Responses:

1. On September 1, 2023, the Company granted 20,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on September 1 of each of 2024, 2025 and 2026. The vested portions of such options will become exercisable upon vesting.

2. On April 18, 2024, the Company granted 50,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting.

3. On April 8, 2025, the Company granted 20,584 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

4. On April 8, 2025, the Company granted 29,416 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

Remarks:

The Reporting Person submitted a completed Form ID application and the related required documents before March 18, 2026, did not receive access to the Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) by March 18, 2026, and is filing this report as soon as possible after receiving EDGAR access.

	/s/ Nigel McCracken	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)